First line oral vinorelbine in elderly patients with advanced non-small-cell lung cancer

Autor: J. Alcalde García, J. Martínez Galán, E. Villar Chamorro, M. Cobo Dols, F. Carabante Ocón, I. Alés Díaz, S. Gil Calle, M. Benavides Orgaz, J. J. Bretón García, G. Durán Ogalla, V. Gutiérrez Calderón
Rok vydání: 2007
Předmět:
Zdroj: Oncología (Barcelona) v.30 n.1 2007
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Scopus-Elsevier
Popis: Purpouse: The activity of vinorelbine (VRL) as single agent in treatment-naive inoperable non small cell cancer (NSCLC) patients (pts) has been assessed in several published studies. Oral and intravenous formulation have a linearity of VRL pharmacokinetics with both routes of administration. This is a study with oral VRL in first line advanced NSCLC in elderly pts. Patients and methods: A total of 12 chemonaive elderly pts ≥ 70 years were recruited from October 2005 through to June 2006. Principal inclusion criteria included histologically confirmed advanced NSCLC, performance status ≤ 2, measurable disease, appropriate bone marrow and organ function. The dosage schedule was 60 mg/m 2 once a week for three weeks (first cycle), followed if not toxicity by 80 mg/m 2 once a week, until disease progression or development of unacceptable toxicity. Results: The mean age was 74 years (range: 71 to 79), all males, and all pts stage IV. Histology subtypes: adenocarcinoma in 5 pts, largo cell carcinoma in 1 pts and squamous cell carcinoma in 6 pts. PS (ECOG) distribution was: 3 pts with PS 1, and 9 pts with PS 2. The median weekly VRL doses was 13 (range 3-23). Out of 11 pts receiving the second cycle, 7 patients went a dose escalation to 80 mg/m 2 . The other 4 pts remained at the 60 mg/m2 dose level. There were no complete responses (CR). Two (13%) of 12 patients achieved partial response (PR). There were 6 (50%) stable disease (SD) and 4 (34%) progressive disease (PD). Respect survival, the median follow-up was 4 months (range 1-9 months). Until date, the median survival time (MST) and median progression-free survival had not been reached; and survival and progression-free survival was 66% in both. Treatment with oral VRL in elderly patients was well tolerated, and there were no toxic deaths. No grade 4 toxicities were observed, and grade 3 toxicities were infrequent, exclusively neutropenia in 2 patients and asthenia in other 2 patients. Rest of toxicities were grade 1 or 2. Conclusions: Oral VRL appears to be a reasonable alternative intravenous VRL, both in terms of activity and tolerability in advanced, elderly NSCLC patients.
Databáze: OpenAIRE
Externí odkaz: